肝性脑病降氨治疗进展

肝脏 ›› 2022, Vol. 27 ›› Issue (6): 622-624.

肝性脑病降氨治疗进展

曾伟兰, 汪艳

510515 广州广东省肝纤维化工程技术研究中心;南方医科大学中心实验室;南方医科大学药学院

收稿日期:2022-05-20 出版日期:2022-06-30 发布日期:2022-08-04
通讯作者: 汪艳,Email: yanwang@smu.edu.cn
基金资助:
国家自然科学基金项目(82070589);广东省自然科学基金项目(2022A1515010218);广州市科技计划项目(2022-01-01-11-3028-0062)

Received:2022-05-20 Online:2022-06-30 Published:2022-08-04

摘要/Abstract

摘要： 肝性脑病(HE)是严重肝病患者的常见并发症和死亡原因之一。HE病理生理机制复杂,高氨血症被认为是关键因素之一,但血氨水平与HE严重程度并不完全一致。全身炎性反应、肠内微生态改变,以及内毒素血症等可能与高血氨发生协同作用,共同影响HE进展和结局。HE治疗方案目前仍以降低氨生成和吸收、提高氨清除率为主要策略。基于肝硬化HE患者的降氨药物治疗临床研究发现,促炎因子水平与血氨异常以及HE严重程度密切相关,影响炎性反应可能在降氨药物的HE防治机制中发挥重要作用。合理精细化的HE患者分层,研发联合抗炎作用的降氨治疗新策略、新方法,对进一步提高肝硬化HE防治疗效具有重要价值。

关键词: 肝性脑病, 药物防治, 降氨治疗, 炎性反应

曾伟兰, 汪艳. 肝性脑病降氨治疗进展[J]. 肝脏, 2022, 27(6): 622-624.

参考文献

[1] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology,2014,60:715-735.
[2] Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol, 2011,54:640-649.
[3] Wright G, Noiret L, Olde Damink SW, et al. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int,2011,31:163-175.
[4] Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol,2017,5:142-151.
[5] Manzhalii E, Virchenko O, Falalyeyeva T, et al. Hepatic Encephalopathy Aggravated by Systemic Inflammation. Dig Dis,2019,37:509-517.
[6] Shawcross DL, Wright G, Olde Damink SW, et al. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis,2007,22:125-138.
[7] Tranah TH, Paolino A, Shawcross DL. Pathophysiological mechanisms of hepatic encephalopathy. Clin Liver Dis (Hoboken),2015,5:59-63.
[8] Iebba V, Guerrieri F, Di Gregorio V, et al. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci Rep,2018,8:8210.
[9] Zhang ZG, Zhai HQ, Geng JW, et al. Large-Scale Survey of Gut Microbiota Associated With MHE Via 16S rRNA-Based Pyrosequencing. Am J Gastroenterol,2013,108:1601-1611.
[10] Sung CM, Lin YF, Chen KF, et al. Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome. Cell Mol Gastroenterol Hepatol,2019,8:301-318 e2.
[11] Rocco A, Sgamato C, Compare D, et al. Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Front Cell Dev Biol,2021,9:748253.
[12] Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev,2016:CD003044.
[13] Dhiman RK, Thumburu KK, Verma N, et al. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis. Clin Gastroenterol Hepatol,2020,18:800-812 e25.
[14] Fujiwara Y, Suzuki K, Yusa K, et al. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy. Intern Med,2021,60:1027-1033.
[15] Kang DJ, Kakiyama G, Betrapally NS, et al. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. Clin Transl Gastroenterol,2016,7:e187.
[16] Rahimi RS, Safadi R, Thabut D, et al. Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. Clin Gastroenterol Hepatol,2021,19:2626-2635 e7.
[17] Butterworth RF, Kircheis G, Hilger N, et al. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Exp Hepatol,2018,8:301-313.
[18] Butterworth RF. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis. Metab Brain Dis, 2020,35:75-81.
[19] Sharma BC, Singh J, Srivastava S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol, 2017,32:1234-1239.
[20] Jain A, Sharma BC, Mahajan B, et al. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology,2022,75:1194-1203.